M6A-modified lncRNA HULC promotes osteosarcoma progression by stabilizing GLUT1 mRNA through interaction with TAF15 [0.03%]
HULC通过与TAF15相互作用稳定GLUT1 mRNA促进骨肉瘤进展
Bo Liu,Yang Yue,Chaoqun Cen et al.
Bo Liu et al.
Background: The overexpression of long noncoding RNA (lncRNA) HULC is recognized as an important contributor to osteosarcoma (OS) progression. However, its precise roles and mechanisms in OS remain unclear, necessitating ...
Inhibition of Aurora B induces senescence and potentiates immunotherapy in hepatocellular carcinoma [0.03%]
Aurora B抑制可诱导肝癌细胞衰老并增强免疫疗法疗效
Shanshan Wu,Hui Wang,Chune Yu et al.
Shanshan Wu et al.
Background: Hepatocellular carcinoma (HCC) is a global health challenge, with limited treatment options for advanced-stage patients. Although recent approvals of targeted therapies and immune checkpoint inhibitors (ICIs) ...
TFPI2 expression predicts resistance to immunotherapy plus tyrosine kinase inhibitor and informs first-line therapy selection in metastatic renal cell carcinoma [0.03%]
TFPI2表达可预测免疫治疗联合酪氨酸激酶抑制剂的耐药性并指导一线用药选择（转移性肾细胞癌）
Jiajun Wang,Lingzhi Du,Ying Wang et al.
Jiajun Wang et al.
Purpose: Combinations of anti-PD-1/PD-L1 immunotherapy (IO) and anti-VEGF tyrosine kinase inhibitor (TKI) are recommended as first-line therapy for metastatic renal cell carcinoma (RCC). We aimed to evaluate the predictiv...
Targeting tumor-associated G-protein coupled receptors: beyond single-axis inhibition toward multidimensional regulation [0.03%]
靶向肿瘤相关G蛋白偶联受体：从单一途径抑制到多维度调节
Xia Zhou,Bilin Tan,Tingting Zhang et al.
Xia Zhou et al.
G protein-coupled receptors (GPCRs) serve as central hubs in tumor signal transduction and microenvironment regulation. However, their therapeutic exploitation is confounded by a fundamental complexity: GPCR functions are exquisitely contex...
Platelet-neutrophil cooperation in cancer: mechanisms of metastatic niche formation and implications for prognostic stratification and therapy [0.03%]
血小板和中性粒细胞在癌症中的合作：转移生态位形成的机制及其对预后分层和治疗的意义
Na Yang,Jiahui Gong,Chang Ge et al.
Na Yang et al.
Metastasis remains the leading cause of cancer-related mortality and arises from ongoing interactions between malignant cells and their surrounding microenvironment. Among host factors, platelets and neutrophils have emerged as key regulato...
NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation [0.03%]
NAA50介导的SLU7稳定通过调节MAP3K3 mRNA核输出和p38 MAPK激活促进膀胱癌顺铂耐药性
Benlin Wang,Xianchong Zheng,Qingsheng Hua et al.
Benlin Wang et al.
Background: Cisplatin-based chemotherapy is first-line for muscle-invasive bladder cancer (BLCA), but chemoresistance remains the primary barrier to clinical efficacy. RNA-binding proteins (RBPs) orchestrate post-transcri...
Machine learning-based integrative analysis identifies CXCL13-driven tertiary lymphoid structures as favorable immune and prognostic features in osteosarcoma [0.03%]
基于机器学习的综合分析识别CXCL13驱动的三级淋巴样结构在骨肉瘤中为有利的免疫和预后特征
Jie Jiang,Jiuhui Xu,Lu Xie et al.
Jie Jiang et al.
Background: Osteosarcoma, an aggressive bone malignancy with limited response to immunotherapy, remains a major clinical challenge. Tertiary lymphoid structures (TLS), as organized ectopic lymphoid aggregates, play a pivo...
CTMP-REV7 axis modulates MHC-I antigen presentation via CDK1-AKT crosstalk in MSI-L/MSS colorectal cancer [0.03%]
CTMP-REV7轴通过CDK1-AKT串扰调节微卫星不稳定低型/微卫星稳定型结直肠癌的MHC-I类抗原呈递
Cheng Gu,Rong He,Xiaolan Yin et al.
Cheng Gu et al.
Purpose: Microsatellite instability-low/microsatellite stable (MSI-L/MSS) colorectal cancer (CRC) exhibits limited responsiveness to immune checkpoint inhibitors due to low tumor mutational burden and insufficient neoanti...
EZH2 inhibition triggers a context-specific ACSS2-H3K9ac-HK2 metabolic circuit in EZH2 non-mutant solid tumors [0.03%]
EZH2抑制通过ACSS2-H3K9ac-HK2代谢回路在非EZH2突变实体瘤中产生特定的上下文反应
Xiaoyun Lin,Yue Song,Qingqin Peng et al.
Xiaoyun Lin et al.
Background & objectives: EZH2 inhibitors show limited efficacy in solid versus hematologic cancers, but the underlying mechanisms are unknown. We investigated whether tumor-type-specific adaptive responses underlie this d...
USP10 confers lenvatinib resistance in hepatocellular carcinoma by deubiquitinating the GPX2 [0.03%]
去泛素化酶USP10通过去泛素化GPX2介导肝细胞癌获得仑伐替尼耐药性
Cheng-Rui Zhong,Zhiyu Qiu,Ya-Jun Tang et al.
Cheng-Rui Zhong et al.
Background: Lenvatinib is a first-line treatment for advanced hepatocellular carcinoma (HCC), yet the development of resistance constitutes a major therapeutic obstacle. While Ubiquitin-specific peptidase 10 (USP10) has b...